articleNew England Journal of MedicineFeb 22, 2023GREEN OA

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

National Health Laboratory Service · University of the Witwatersrand · +27 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Background

Valoctocogene roxaparvovec delivers a B-domain-deleted factor VIII coding sequence with an adeno-associated virus vector to prevent bleeding in persons with severe hemophilia A. The findings of a phase 3 study of the efficacy and safety of valoctocogene roxaparvovec therapy evaluated after 52 weeks in men with severe hemophilia A have been published previously.

Methods

vector genomes of valoctocogene roxaparvovec per kilogram of body weight. The primary end point was the change from baseline in the annualized rate of treated bleeding events at week 104 after receipt of the infusion. The pharmacokinetics of valoctocogene roxaparvovec were modeled to estimate the bleeding risk relative to the activity of transgene-derived factor VIII.

No related works found for this paper.

Funding